FDA Drug Safety Office Needs Better System To Track Recommendations
Executive Summary
An internal review of FDA's Office of Drug Safety has identified follow-up on recommendations as a central area for improvement, Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman told a July 20 meeting of the Institute of Medicine Committee on the Assessment of the U.S. Drug Safety System
You may also be interested in...
One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA
One year after the withdrawal of Vioxx, FDA appears to be rebalancing its focus from a heightened emphasis on safety towards a greater appreciation of the emerging efficacy of drugs
One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA
One year after the withdrawal of Vioxx, FDA appears to be rebalancing its focus from a heightened emphasis on safety towards a greater appreciation of the emerging efficacy of drugs
Erectile Dysfunction Class Labeling Excludes Causal Link To Vision Loss
FDA's class labeling for oral erectile dysfunction disorder drugs on the incidence of non-arteritic anterior ischemic optic neuropathy notes that it is unknown whether the drugs are connected to the adverse events